Spectrazyme, 180 count, 60 count, 12 bottles/case, 20000 tablets/box, 14000 capsules/pail.

Metagenics, INC. recalled Spectrazyme, 180 count, 60 count, 12 bottles/case, 20000 tablets/box, 14000 capsules/pail. in a Class II action, the FDA tier for products that may cause temporary or medically reversible health effects on Oct 11, 2013.

The FDA-published reason for this recall is: "Metagenics is recalling Spectrazyme because their raw material supplier informed them that enzymes in the blend may contain the antibiotic chloramphenicol."

Distribution was broad: the FDA record describes it as "Nationwide in US and worldwide to Japan, Taiwan, Belgium, and Canada," which places this among the wider-reach recalls on the site. Consumers across the affected area should check product on hand. The recalling firm is based in Aliso Viejo, CA. The recall covers 1,171,300 units of product. The FDA has Terminated this recall (first reported Nov 20, 2013), its final lifecycle state, indicating the agency considers the corrective action resolved. The historical record remains useful for tracking a brand's recall pattern over time.